Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 2/20 | 0.39 |
| ▸ | OPRM1 | P35372 | 4/20 | 0.36 |
| ▸ | SCN4A | P35499 | 1/20 | 0.36 |
| ▸ | GLA | P06280 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | SLC6A9 | P48067 | 2/20 | 0.34 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.34 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.34 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.34 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.34 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.34 |
| ▸ | CCR5 | P51681 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | MCOLN3 | Q8TDD5 | 1/20 | 0.34 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2815309 | 0.90 | HTT (0.39) | HTTOPRM1SCN4AP2RX7CCR5 | |
| SCHEMBL28459274 | 0.85 | GAA (0.36) | HTTOPRM1MEN1LMNAMAPT | |
| SCHEMBL21769890 | 0.84 | HTT (0.36) | HTTOPRM1SCN4AGLASMN1; SMN2 | |
| SCHEMBL2773909 | 0.80 | CNR2 (0.45) | HTTSMN1; SMN2NPSR1NR1H4ALDH1A1 | |
| SCHEMBL28453946 | 0.78 | KDM4E (0.39) | HTTGLASMN1; SMN2MEN1LMNA | |
| SCHEMBL14000159 | 0.75 | MAPT (0.37) | HTTSMN1; SMN2MEN1MAPTKMT2A | |
| SCHEMBL6170917 | 0.74 | KEAP1 (0.43) | HTTOPRM1SMN1; SMN2LMNAMAPT | |
| SCHEMBL14000191 | 0.74 | SLC6A9 (0.43) | SLC6A9 | |
| SCHEMBL21769856 | 0.72 | L3MBTL1 (0.38) | MEN1LMNAMAPTKMT2AALDH1A1 | |
| SCHEMBL29031636 | 0.71 | CNR2 (0.49) | HTTOPRM1SCN4ASMN1; SMN2P2RX7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108623577-B | Preparation method of amonebvir and intermediate thereof | 山东百诺医药股份有限公司 | 2020-09-25 | — | — | CN | disclosed |
| EP-1857108-B1 | PREVENTIVE OR THERAPEUTIC AGENT FOR HERPESVIRUS-RELATED DISEASE | ASTELLAS PHARMA INC (JP) | 2010-12-08 | — | — | EP | disclosed |
| EP-1844775-B1 | THERAPEUTIC AGENT FOR THE TREATMENT OF HERPES PROGENITALIS AFTER DEVELOPMENT OF LESIONS | ASTELLAS PHARMA INC (JP) | 2010-08-11 | — | — | EP | disclosed |
| EP-1844776-B1 | AGENT FOR PREVENTION/TREATMENT OF DISEASE CAUSED BY ACYCLOVIR-RESISTANT HERPESVIRUS | ASTELLAS PHARMA INC (JP) | 2010-04-28 | — | — | EP | disclosed |
| US-20090048310-A1 | AGENT FOR PREVENTION/TREATMENT OF DISEASE CAUSED BY ACYCLOVIR-RESISTANT HERPESVIRUS | ASTELLAS PHARMA INC. (JP) | 2009-02-19 | — | — | US | disclosed |
| US-20090042915-A1 | PREVENTIVE OR THERAPEUTIC AGENT FOR HERPESVIRUS-RELEATED DISEASE | ASTELLAS PHARMA INC. (JP) | 2009-02-12 | — | — | US | disclosed |
| US-20090030049-A1 | MEDICAMENT FOR GENITAL HERPES | ASTELLAS PHARMA INC. (JP) | 2009-01-29 | — | — | US | disclosed |
| US-7465748-B2 | Antiherpesvirus drugs; great pharmacokinetics, good antivirus activity when administered orally at a low dose, high safety profile, less mutagenic concerns; N-(2,6-dimethylphenyl)-N-(2-{[4-(1,3-oxazol-4-yl)phenyl]amino)-2-oxoethyl)tetrahydro-2H-thiopyran-4-carboxamide 1,1-dioxide | ASTELLAS PHARMA INC. (JP) | 2008-12-16 | — | — | US | disclosed |
| EP-1857108-A1 | PREVENTIVE OR THERAPEUTIC AGENT FOR HERPESVIRUS-RELATED DISEASE | Astellas Pharma Inc. (JP) | 2007-11-21 | — | — | EP | disclosed |
| EP-1844775-A1 | THERAPEUTIC AGENT FOR HERPES PROGENITALIS | Astellas Pharma Inc. (JP) | 2007-10-17 | — | — | EP | disclosed |
| EP-1844776-A1 | AGENT FOR PREVENTION/TREATMENT OF DISEASE CAUSED BY ACYCLOVIR-RESISTANT HERPESVIRUS | Astellas Pharma Inc. (JP) | 2007-10-17 | — | — | EP | disclosed |
| US-20060229295-A1 | Amide derivatives | ASTELLAS PHARMA INC.AND RATIONAL DRUG DESIGN (JP) | 2006-10-12 | — | — | US | disclosed |
| EP-1652843-A1 | AMIDE DERIVATIVES | Astellas Pharma Inc. (JP) | 2006-05-03 | — | — | EP | disclosed |
| US-6903125-B2 | Tetrahydro-2H-thiopyran-4-carboxamide derivative | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 2005-06-07 | — | — | US | disclosed |
| US-20050032855-A1 | Tetrahydro-2H-thiopyran-4-carboxamide derivative | YAMANOUCHI PHARMACEUTICAL CO., LTD. | 2005-02-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090048310-A1 | AGENT FOR PREVENTION/TREATMENT OF DISEASE CAUSED BY ACYCLOVIR-RESISTANT HERPESVIRUS | ZC3HAV1, ZC3HAV1L, GRIK2 | HTT 4097/4885OPRM1 3991/4885SCN4A 796/4885 |
| US-20050032855-A1 | Tetrahydro-2H-thiopyran-4-carboxamide derivative | TPMT, RPL35, TYMP | HTT 2375/4885OPRM1 2830/4885SCN4A 851/4885 |
| US-20060229295-A1 | Amide derivatives | VAC14, HDAC8, ZC3HAV1 | HTT 4097/4885OPRM1 3196/4885SCN4A 534/4885 |
| US-20090042915-A1 | PREVENTIVE OR THERAPEUTIC AGENT FOR HERPESVIRUS-RELEATED DISEASE | RECQL, DNA2, DHX35 | HTT 1621/4885OPRM1 4827/4885SCN4A 3884/4885 |
| US-20090030049-A1 | MEDICAMENT FOR GENITAL HERPES | TK1, TYMP, RPL23 | HTT 4840/4885OPRM1 3302/4885SCN4A 2529/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.